0001104659-23-092843.txt : 20230817 0001104659-23-092843.hdr.sgml : 20230817 20230817065908 ACCESSION NUMBER: 0001104659-23-092843 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230817 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230817 DATE AS OF CHANGE: 20230817 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EAGLE PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000827871 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36306 FILM NUMBER: 231179774 BUSINESS ADDRESS: STREET 1: 50 TICE BOULEVARD, SUITE 315 CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 BUSINESS PHONE: 201-326-5300 MAIL ADDRESS: STREET 1: 50 TICE BOULEVARD, SUITE 315 CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 FORMER COMPANY: FORMER CONFORMED NAME: EAGLE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19880120 8-K 1 tm2324015d1_8k.htm FORM 8-K
0000827871 false 0000827871 2023-08-17 2023-08-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 17, 2023

 

Eagle Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 001-36306 20-8179278
(State or other jurisdiction (Commission File Number) (IRS Employer Identification No.)
of incorporation)    

 

50 Tice Boulevard, Suite 315
Woodcliff Lake, NJ		   07677
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (201) 326-5300

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock (par value $0.001 per share)   EGRX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On August 17, 2023, Eagle Pharmaceuticals, Inc., or the Company, issued a press release reiterating certain of its financial guidance for fiscal year 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibit No.   Description
99.1   Press Release of the Company, dated August 17, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: August 17, 2023 EAGLE PHARMACEUTICALS, INC.
   
  By: /s/ Scott Tarriff
    Scott Tarriff
    Chief Executive Officer

 

 

 

 EX-99.1 2 tm2324015d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Eagle Pharmaceuticals Reiterates 2023 Adjusted non-GAAP EBITDA and Adjusted non-GAAP EPS1 Guidance

 

-- FY 2023 Adjusted non-GAAP EBITDA expected to be $78.0 - $84.0 million1 --

-- FY 2023 Adjusted non-GAAP earnings per share expected to be $4.40 - $4.701 --

-- Reflects strength of Eagle’s business and product pipeline; Company poised for sustained long-term growth –

 

WOODCLIFF LAKE, N.J. — August 17, 2023 — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today reiterated its previously issued guidance for the 2023 fiscal year. Full-year 2023 Adjusted non-GAAP EBITDA is expected to range from $78.0 to $84.0 million and Adjusted non-GAAP earnings per share is expected to range from $4.40 to $4.70.

 

“Based on the strength of our business and product pipeline, we are reiterating our recently increased guidance and believe Eagle is on the path to generating sustained long-term growth,” stated Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals.

 

About Eagle Pharmaceuticals, Inc.

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and Byfavo® and Barhemsys® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.

 

 

1 Adjusted EBITDA and adjusted non-GAAP earnings per share are non-GAAP financial measures. For descriptions of these non-GAAP financial measures, please see below.

 

 

 

 

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities law. Forward-looking statements are statements that are not historical facts. Words and phrases such as “anticipated,” “forward,” “will,” “would,” “could,” “may,” “remain,” “potential,” “prepare,” “expected,” “believe,” “plan,” “near future,” “belief,” “guidance,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the Company’s financial projections and guidance, including anticipated financial performance for 2023, including expected adjusted EBITDA and adjusted non-GAAP earnings per share; the Company’s ability to sustain longterm growthand the potential of the Company’s pipeline and product candidates to address underserved therapeutic areas across multiple disease states. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the Company’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks and uncertainties include, but are not limited to: the impacts of the post- COVID-19 environment and geopolitical factors such as the conflict in Ukraine; delay in or failure to obtain regulatory approval of the Company's or its partners’ product candidates and successful compliance with FDA, European Medicines Agency and other governmental regulations applicable to product approvals; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; whether the Company can successfully market and commercialize its product candidates; the success of the Company's relationships with its partners; the outcome of litigation involving any of its products or that may have an impact on any of its products; the strength and enforceability of the Company’s intellectual property rights or the rights of third parties; competition from other pharmaceutical and biotechnology companies and the potential for competition from generic entrants into the market; unexpected safety or efficacy data observed during clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the risks inherent in drug development and in conducting clinical trials; unanticipated factors in addition to the foregoing that may impact the Company’s financial and business projections and guidance and may cause the Company’s actual results and outcomes to materially differ from its projections and guidance; and those risks and uncertainties identified in the “Risk Factors” sections of the Company's Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (the “SEC”) on March 23, 2023, the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed with the SEC on May 9, 2023, the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed with the SEC on August 8, 2023 and its other subsequent filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 

Non-GAAP Financial Performance Measures

This press release contains guidance as to adjusted non-GAAP EBITDA and adjusted non-GAAP earnings per share. The Company believes these measures provide investors and management with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect to projected information.

 

Adjusted non-GAAP net income and related earnings per share information excludes amortization expense, stock-based compensation expense, depreciation expense, severance expense, non-cash interest expense, fair value adjustments on equity investment, fair value adjustments related to derivative instruments, foreign currency exchange gain or loss, amortization of inventory step-up, and the tax effect of these adjustments.

 

 

 

 

Adjusted non-GAAP EBITDA excludes interest expense net of interest income, income tax provision, depreciation and amortization expense, stock-based compensation expense, fair value adjustments on equity investment, fair value adjustments related to derivative instruments, foreign currency exchange gain or loss, and severance expense.

 

The Company believes the use of non-GAAP financial measures helps indicate underlying trends in the Company’s business and are important in comparing current results with prior period results and understanding projected operating performance. Non-GAAP financial measures provide the Company and its investors with an indication of the Company’s baseline performance before items that are considered by the Company not to be reflective of the Company’s ongoing results.

 

Investors should note that reconciliations of the forward-looking or projected non-GAAP financial measures included in this press release to their most comparable GAAP financial measures cannot be provided because the Company cannot do so without unreasonable efforts due to the unavailability of information needed to calculate the reconciling items and the variability, complexity, and limited visibility of comparable GAAP measures, and the reconciling items that would be excluded from the non-GAAP financial measures in the future. Likewise, the Company is unable to provide projected GAAP financial measures. GAAP projections and reconciliations of the components of projected adjusted non-GAAP EBITDA and adjusted non-GAAP earning per share to their most comparable GAAP financial measures are not provided because the quantification of projected net income and earnings per share and the reconciling items between projected GAAP to adjusted non-GAAP EBITDA and adjusted non-GAAP earnings per share cannot be reasonably calculated or predicted at this time without unreasonable efforts. For example, with respect to GAAP net income, the Company is not able to calculate the favorable or unfavorable expenses related to the fair value adjustments on equity investments and derivative instruments primarily due to nature of these transactions. Such unavailable information could be significant such that actual GAAP net income and earnings per share would vary significantly from projected GAAP and adjusted non-GAAP EBITDA and adjusted non-GAAP earnings per share.

 

These non-GAAP financial measures should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. In addition, from time to time in the future there may be other items that the Company may exclude for purposes of its non-GAAP financial measures; and the Company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. For example, commencing in 2023, the Company no longer excludes expense of acquired in-process research & development from the Company’s adjusted non-GAAP net income or adjusted non-GAAP EBITDA, their line item components, and non-GAAP earnings per share. Likewise, the Company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. The Company strongly encourages investors to review its consolidated financial statements and publicly-filed reports in their entirety and cautions investors that the non-GAAP financial measures used by the Company may differ from similar measures used by other companies, even when similar terms are used to identify such measures.

 

Investor Relations for Eagle Pharmaceuticals, Inc.:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

 

 

 

 EX-101.SCH 3 egrx-20230817.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 egrx-20230817_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 egrx-20230817_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2324015d1_ex99-1img004.jpg GRAPHIC begin 644 tm2324015d1_ex99-1img004.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 17, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 17, 2023
Entity File Number 001-36306
Entity Registrant Name Eagle Pharmaceuticals, Inc.
Entity Central Index Key 0000827871
Entity Tax Identification Number 20-8179278
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 50 Tice Boulevard
Entity Address, Address Line Two Suite 315
Entity Address, City or Town Woodcliff Lake
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07677
City Area Code 201
Local Phone Number 326-5300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock (par value $0.001 per share)
Trading Symbol EGRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2324015d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000827871 2023-08-17 2023-08-17 iso4217:USD shares iso4217:USD shares 0000827871 false 8-K 2023-08-17 Eagle Pharmaceuticals, Inc. DE 001-36306 20-8179278 50 Tice Boulevard Suite 315 Woodcliff Lake NJ 07677 201 326-5300 false false false false Common Stock (par value $0.001 per share) EGRX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / " M 6\0 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " !D-Q%7)!Z;HJT #X M 0 &@ @ '/$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'-02P$"% ,4 " !D-Q%799!YDAD! #/ P $P @ &T L$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #^$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://eagleus.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2324015d1_8k.htm egrx-20230817.xsd egrx-20230817_lab.xml egrx-20230817_pre.xml tm2324015d1_ex99-1.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2324015d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2324015d1_8k.htm" ] }, "labelLink": { "local": [ "egrx-20230817_lab.xml" ] }, "presentationLink": { "local": [ "egrx-20230817_pre.xml" ] }, "schema": { "local": [ "egrx-20230817.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "egrx", "nsuri": "http://eagleus.com/20230817", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2324015d1_8k.htm", "contextRef": "AsOf2023-08-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://eagleus.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2324015d1_8k.htm", "contextRef": "AsOf2023-08-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eagleus.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-092843-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-092843-xbrl.zip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